KR20170070272A - 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법 - Google Patents

항신경성 성장 인자 항체 및 그의 제조방법과 이용방법 Download PDF

Info

Publication number
KR20170070272A
KR20170070272A KR1020177016066A KR20177016066A KR20170070272A KR 20170070272 A KR20170070272 A KR 20170070272A KR 1020177016066 A KR1020177016066 A KR 1020177016066A KR 20177016066 A KR20177016066 A KR 20177016066A KR 20170070272 A KR20170070272 A KR 20170070272A
Authority
KR
South Korea
Prior art keywords
ser
thr
antibody
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177016066A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 기어링
Original Assignee
넥스베트 오스트레일리아 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥스베트 오스트레일리아 피티와이 리미티드 filed Critical 넥스베트 오스트레일리아 피티와이 리미티드
Publication of KR20170070272A publication Critical patent/KR20170070272A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020177016066A 2011-05-06 2012-05-08 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법 Ceased KR20170070272A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161483488P 2011-05-06 2011-05-06
US61/483,488 2011-05-06
US201161531439P 2011-09-06 2011-09-06
US61/531,439 2011-09-06
PCT/GB2012/051003 WO2012153122A1 (en) 2011-05-06 2012-05-08 Anti-nerve growth factor antibodies and methods of preparing and using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137032544A Division KR101783929B1 (ko) 2011-05-06 2012-05-08 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법

Publications (1)

Publication Number Publication Date
KR20170070272A true KR20170070272A (ko) 2017-06-21

Family

ID=46168540

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177016066A Ceased KR20170070272A (ko) 2011-05-06 2012-05-08 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
KR1020137032544A Active KR101783929B1 (ko) 2011-05-06 2012-05-08 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137032544A Active KR101783929B1 (ko) 2011-05-06 2012-05-08 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법

Country Status (13)

Country Link
US (2) US9328164B2 (enExample)
EP (2) EP3498732B1 (enExample)
JP (1) JP6258194B2 (enExample)
KR (2) KR20170070272A (enExample)
CN (1) CN103732621B (enExample)
AU (1) AU2012252152B2 (enExample)
BR (1) BR112013028655B1 (enExample)
ES (1) ES2704037T3 (enExample)
GB (1) GB2504887B (enExample)
MY (1) MY161394A (enExample)
RU (1) RU2640254C2 (enExample)
SG (2) SG194793A1 (enExample)
WO (1) WO2012153122A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
MX359070B (es) 2010-12-01 2018-09-13 Alderbio Holdings Llc Composiciones anti-ngf y uso de las mismas.
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
EP2983711A4 (en) * 2013-04-08 2016-11-23 Cytodyn Inc FELLINED ANTIBODIES AND METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES
PT3083694T (pt) 2013-12-20 2024-02-01 Intervet Int Bv Anticorpos murinos caninizados anti-pd-1 canino
AU2015326996B2 (en) 2014-09-30 2021-05-20 Intervet International B.V. PD-L1 antibodies binding canine PD-L1
MX394954B (es) * 2015-05-22 2025-03-24 Astellas Pharma Inc Fragmento fab de anticuerpo anti-ngf humano novedoso.
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
EP3390451B1 (en) 2015-12-18 2025-01-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
KR102569068B1 (ko) * 2016-08-15 2023-08-21 국립대학법인 홋가이도 다이가쿠 항pd-l1 항체
CA3033900A1 (en) * 2016-08-15 2018-02-22 National University Corporation Hokkaido University Anti-pd-1 antibody
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3765499A1 (en) * 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
CN110283246A (zh) * 2019-06-20 2019-09-27 长春西诺生物科技有限公司 一种抗猫细小病毒的猫源化基因工程抗体
WO2021041972A1 (en) * 2019-08-29 2021-03-04 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
EP4114856A4 (en) * 2020-03-03 2023-11-22 Scout Bio, Inc. ANTIGEN BINDING MOLECULES AND THEIR USES
MX2023000500A (es) 2020-07-10 2023-04-12 Invetx Inc Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso.
KR20240006586A (ko) 2021-05-12 2024-01-15 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Rankl 및 ngf에 특이적으로 결합하는 항원 결합 분자, 및 이의 의학적 용도
WO2023034880A2 (en) 2021-08-31 2023-03-09 Scout Bio, Inc. Antigen-binding molecules and uses thereof
WO2024145280A2 (en) 2022-12-27 2024-07-04 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
GB9202796D0 (en) 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1268794A2 (en) 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
JP2005514063A (ja) * 2001-12-21 2005-05-19 イデックス ラボラトリーズ インコーポレイテッド イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
HRP20050721A2 (en) 2003-02-19 2007-03-31 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
MXPA06011463A (es) * 2004-04-07 2007-04-25 Rinat Neuroscience Corp Metodos para tratar dolor por cancer de hueso al administrar un antagonista de factor de crecimiento de nervio.
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
RU2503720C2 (ru) * 2008-01-11 2014-01-10 Астеллас Фарма Инк. УЛУЧШЕННОЕ ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ α9-ИНТЕГРИНУ
EP2331579B1 (en) * 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
US20110300068A1 (en) * 2009-01-12 2011-12-08 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of cancer
EP2411050A4 (en) 2009-03-25 2013-07-17 Vet Therapeutics Inc ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US9505829B2 (en) * 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
CA2927952C (en) * 2013-10-23 2022-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule imaging of fungi by positron emission tomography scanning

Also Published As

Publication number Publication date
MY161394A (en) 2017-04-14
EP3498732B1 (en) 2021-11-17
RU2013154301A (ru) 2015-06-20
EP3498732A1 (en) 2019-06-19
SG10201500953YA (en) 2015-04-29
NZ617447A (en) 2015-01-30
KR101783929B1 (ko) 2017-10-11
RU2640254C2 (ru) 2017-12-27
AU2012252152B2 (en) 2016-07-07
KR20140047048A (ko) 2014-04-21
EP2705055A1 (en) 2014-03-12
CN103732621B (zh) 2020-04-24
ES2704037T3 (es) 2019-03-13
GB201320046D0 (en) 2013-12-25
EP2705055B1 (en) 2018-11-14
JP6258194B2 (ja) 2018-01-10
BR112013028655B1 (pt) 2022-08-16
BR112013028655A8 (pt) 2017-12-26
GB2504887B (en) 2016-02-03
BR112013028655A2 (pt) 2016-11-29
CN103732621A (zh) 2014-04-16
US20140147439A1 (en) 2014-05-29
AU2012252152A1 (en) 2013-11-14
JP2014519317A (ja) 2014-08-14
US9328164B2 (en) 2016-05-03
US20160272701A1 (en) 2016-09-22
SG194793A1 (en) 2013-12-30
WO2012153122A1 (en) 2012-11-15
GB2504887A (en) 2014-02-12

Similar Documents

Publication Publication Date Title
KR101783929B1 (ko) 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
KR101783398B1 (ko) 항신경성 성장인자 항체 및 그의 제조방법과 이용방법
KR101833465B1 (ko) 항신경 성장 인자 항체 및 그의 제조방법과 이용방법
CA2835094C (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
JP2017101064A (ja) 抗神経成長因子抗体並びに前記抗体の製造及び使用方法
EP4026845A1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195570A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
NZ617447B2 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781B (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195781A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK1195571A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170612

Application number text: 1020137032544

Filing date: 20131206

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170911

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180512

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170911

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I